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Abstract
Background: Squamous cell carcinoma of esophagus (SCCE) occurs at a high incidence rate in
certain parts of the world. This feature necessitates that different aspects of the disease and in
particular genetic characteristics be investigated in such regions. In addition, such investigations
might lead to achievement of molecular markers helpful for early detection, successful treatment
and follow up of the disease. Adenomatous Polyposis Coli (APC) promoter hypermethylation has
been shown to be a suitable marker for both serum and solid tumors of adenocarcinoma of
esophagus. We investigated the status of APC promoter hypermethylation in Iranian patients,
compared the results with the former studies, and evaluated its applicability as a candidate
molecular marker by examining association between survival of SCCE patients and APC promoter
methylation.
Methods: For evaluating the status of APC promoter hypermethylation and its association with
SCCE, a qualitative methylation specific PCR (MSP) was used. DNA was extracted and digested
with an appropriate restriction enzyme, treated with sodium bisulfite in agarose beads and
amplified in two-step PCR reaction by applying either methylated or unmethylated promoter
specific primers. Universally methylated DNA and methylase treated blood DNA of healthy donors
were used as positive controls as well. Survival of patients was followed up for two years after
treatment and survival rate of patients with methylated APC promoter was compared with that of
unmethylated patients.
Results:  Assessment of APC  promoter methylation revealed that normal tissues were
unmethylated, while twenty out of forty five (44.4%) tumor tissues were hypermethylated either in
one or both alleles of APC. Among the tissues in which methylation was detected, seven were
hypermethylated in both alleles while the other thirteen were hypermethylated in one of the two
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alleles of APC. Analyzing two-year survival rate of patients with respect to promoter
hypermethylation showed a lower rate of survival for patients with methylated APC promoter
following their treatment. Further investigation into the association between promoter
hypermethylation and tumor differentiation status indicated that patients with well differentiated
tumors were more likely to develop promoter hypermethylation.
Conclusion: Observing similar level of APC promoter hypermethylation in patients with SCCE in
this high risk region and comparing it with other parts of the world could support the hypothesis
that a common molecular mechanism might be involved in tumorigenesis of SCCE. In addition, the
higher rate of two-year survival for patients with unmethylated APC promoter as well as its
relationship with tumor differentiation would suggest that this tumor suppressor could be an
appropriate candidate molecular marker for evaluating tumor malignancy and predicting survival of
patients subsequent to treatment.
Background
A high incidence rate of SCCE has been reported for the
so-called Asian esophageal cancer belt; the highest rate of
which was reported from Iran [1-5]. In addition, recent
reports have evidenced an increasing incidence of esopha-
geal cancer in developed countries, especially adenocarci-
noma of esophagus [6-8]. Several genetic and epigenetic
alterations have been suggested to play an important role
in the carcinogenesis of esophageal and other gastrointes-
tinal (GI) tumors; affecting different oncogenes, tumor
suppressor genes, apoptosis regulating genes or mismatch
repair genes such as APC, P53, P16, DCC, RB, MCC, BRCA
and  MTS1/CDK41  [9-18]. Hypermethylation of CpG
islands in promoter regions of genes is a common epige-
netic event of gene silencing in both types of esophageal
cancers and impacts a wide range of important genes such
as those involved in matrix remodeling like TIMP3
[19,20], ligand dependent suppressor genes for instance
DCC  [21], cell adhesion genes including cadherins
(CDH1) and integrins [22-24], cell cycle regulator genes
such as p14, p16 [20,23,24], apoptosis associated genes
like DAPK, DNA repair and mismatch repair genes such as
MGM, hMLH1 [20,23-25], xenobiotic metabolism
engaged genes for instance GSTP1 [24] and nel-like1gene
[26]. Epigenetic silencing of tumor suppressor genes has
been shown to be associated with tumor invasiveness,
growth, neovascularization, metastatic behavior and in
particular, might be the cause of tumor recurrence after
treatment, impacting overall patient survival [27-30].
Among those genes which are subject of epigenetic regu-
lation, APC promoter hypermethylation occurs in all
organs of GI cancers, both in hereditary and sporadic syn-
dromes. This might indicate the importance of APC inac-
tivation in tumorigenesis of these organs [31]. Moreover,
recent reports indicate that APC is an important prognos-
tic indicator for unfavorable clinicopathological outcome
and tumor recurrence in several types of cancers [29,30].
APC along with several other hypermethylated genes play
a prognostic indicatory role in squamous cell [22] and
adenocarcinoma of esophagus [26], bladder [30], and
lung cancers [29]. In fact, in adenocarcinoma of esopha-
gus, APC promoter hypermethylation has been observed
in 92% of cases [32]. This indicates that inactivation of
APC plays a key role in the carcinogenesis of esophageal
cancers and could be considered as a candidate molecular
marker.
The Adenomatous Polyposis Coli (APC) tumor suppres-
sor gene, maps on chromosome 5q21-22, has been inves-
tigated in several types of cancers and in particular
colorectal cancers. While loss of heterozygosity
[11,18,33,34] along with mutational inactivation [35,36]
has been suggested for APC in esophageal cancer, never-
theless, mutations in APC are rare in this cancer [37-39].
Investigations have shown that inactivation of APC leads
to increased β-catenin transcriptional activity and subse-
quent loss of cellular growth control. In normal cells, free
β-catenin anchors to APC tripartite complex, composed of
Axin-APC-GSK3-β and undergoes phosphorylation by
glycogen synthase kinase3-β (GSK3-β), followed by pro-
teasomal degradation, which results in reduction of free β-
catenin in cytoplasm and thus, leading to silencing of the
Wnt signaling target genes [40]. In contrast, loss of APC
results in nuclear accumulation of β-catenin, which subse-
quently binds to Tcf-Lef (T cell factor/lymphoid enhancer
factor) family of transcription factors, culminating in the
activation of transcription and ultimately uncontrolled
cell growth [41,42].
With regards to epigenetic regulation of APC and other
tumor suppressor genes, so far as we know there is no pre-
vious report from this high risk region of the world. This
is the first effort that has focused on epigenetic regulation
of APC as an example of tumor suppressor genes such as
P15INKb. We have recently begun to investigate their possi-
ble roles in carcinogenesis of SCCE in this region. The
present report is the first attempt toward applying qualita-
tive methylation specific PCR to reveal the methylation
status of APC  promoter within an Asian populationBMC Cancer 2009, 9:24 http://www.biomedcentral.com/1471-2407/9/24
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highly at risk for developing SCCE. Our results show that
the frequency of APC promoter methylation is almost the
same as other regions, in particular the Western world.
The results of this study also indicate that APC promoter
methylation could be considered as a potential molecular
marker for follow up the progress and survival of patients
in consequence to their treatment.
Methods
Patients and specimens
45 patients including 27 men ranging in age from 23 to 80
(average of 61.1) and 18 women ranging in age from 45
to73 (average of 61.7) at the time of diagnosis were
included in this study. Tumor tissues along with their
adjacent normal tissues were used for analysis. Tissue
samples were obtained from patients whom had not
received chemo or radiotherapy before operation. Follow-
ing surgery, tissue samples were snap frozen in liquid
nitrogen and kept at -70°C until the time of DNA extrac-
tion. Tissues were included 32 poorly differentiated, 5
moderately and 8 well differentiated tumors according to
the World Health Organization criteria (WHO, 1977). All
samples were diagnosed as SCCE and status of differenti-
ation were confirmed by pathological examination.
Peripheral blood samples of healthy donors were col-
lected as negative control. The same blood samples were
also used for further treatment with DNA methylase for
evaluating bisulfite treatment procedure. The survival rate
of patients was monitored for two years. All patients and
healthy donors of blood samples gave consent according
to institutional guidelines and the study was approved by
the research ethics committee of Digestive Disease
Research Center (DDRC) of Medical University of Tehran.
DNA Isolation and digestion
Genomic DNA was extracted from the ground frozen nor-
mal and tumor tissues following digestion with protein-
ase K and phenol/chloroform protein precipitation
[43,44]. Blood DNA was extracted as previously described
[45]. Subsequently, extracted DNA of either tumor or nor-
mal tissues was digested with Hind III (Fermentase Com-
pany), for which no restriction site is present in the entire
1556 bp of APC  promoter. Digestion with HindIII
enhances DNA denaturation and results in better bisulfite
treatment as well.
Agarose/DNA beads preparation
One μg of the digested genomic DNA was boiled for 5
min, immediately chilled on ice, and subsequently incu-
bated in 0.3 M NaOH for 15 min at 50°C. Two volumes
of the melted 2% low melting point (LMP) agarose
(Roche Company) dissolved in ddH2O were pipetted into
the mixture. DNA/agarose mixtures containing 100–200
ng of DNA were injected into chilled mineral oil to form
agarose beads [46].
Sodium bisulfite treatment of agarose beads
Deamination of DNA was performed using freshly made
bisulfite solution (2.5 M sodium metabisulfite and 125
mM hydroquinone, pH 5) at 50°C in the dark. Bisulfite
treatment of agarose beads at moderate temperature
(50°C), for short time, reduces DNA degradation while
still keeping it in the single stranded conformation
required for complete treatment. Furthermore, since
treated agarose beads could directly be used in PCR reac-
tion, there is no need for precipitation of treated DNA
which usually accompanied by some loss [46-48]. Aliq-
uots of 200 μl bisulfite solution were added to vials con-
taining a single bead and incubated at 50°C for 4 h in the
dark [32,46]. Further treatment was stopped by equilibrat-
ing the beads with TE buffer (10 mM Tris HCL, 1 mM
EDTA, pH 8) for 6 times, each time for 15 min, followed
by desulfonation with 0.2 M NaOH, and neutralization
with 1/5 (V/V) 1 M HCl for 15 min, this procedure was
repeated twice. Finally, each bead containing modified
DNA was washed twice with TE buffer and then twice with
ddH2O, consecutively, each time for 15 min [46]. Beads
were kept in a small volume of TE (pH 8) at 4°C and used
in less than 3 weeks without any effect on the quality of
MSP.
Methylation Specific PCR
Bisulfite treated DNA from either of following samples
was used in methylation specific PCR [49]. Samples were
composed of normal and tumor tissues along with blood
of healthy donors as negative control. In addition, meth-
ylated DNA (CpGenome Universal methylated DNA,
Chemicon) and blood DNA modified by CpG methylase
(New England Biolabs) were used as positive control and
control of bisulfite treatment efficiency.
Methylation specific PCR was carried out using promoter
1A of APC in two-step amplification procedure. A primary
amplification was followed by secondary methylation
specific PCR. Bisulfite treatment was performed before
primary amplification because DNA polymerase uses
deoxycytosine in the reaction mixture wherever a guanine
is present in the template. As a result, it becomes impossi-
ble to discriminate methylated from unmethylated
cytosines if bisulfite treatment is done after primary
amplification. Moreover, treatment after primary amplifi-
cation also results in loss or degradation of DNA. For pri-
mary amplification, the region of promoter 1A without
CpG dinucleotides was used for forward and reverse
primer design. This approach not only verifies proper
treatment of DNA but also provides an adequate template
for the second round of PCR, in which methylated
cytosines are differentiated from unmethylated ones by
applying methylated CpG dinucleotides specific primers.
Two sets of primers were designed for primary amplifica-
tion. The first set of primers were the forward primer; 5'-BMC Cancer 2009, 9:24 http://www.biomedcentral.com/1471-2407/9/24
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TTT GTT TGT TGG GGA TTG GGG T-3', and the reverse
primer; 5'-AAA CCC TAT ACC AAA AAA AAA CCA TC-3',
resulting in a product of 402 bp. The second set of primers
for primary amplification were the forward primer; 5'-GTT
AGG GTT AGG TAG GTT GTG-3', and the reverse primer;
5'-AAA ACA ATA CAA AAA AAA ACC ACC TTC-3', leading
to a 320 bp product. Bisulfite treated DNA was amplified
in a 50 μl reaction volume containing 1× reaction buffer,
0.2 mM each dNTP, 1 mM MgCl2, 8 mM β-mercaptoeth-
anol (2-ME), 0.8 μg/ml bovine serum albumin (BSA), 8%
dimethyl sulphoxide (DMSO) and 20 pmol/reaction of
either sets of primers designed for primary amplification.
Applying a mixture of several PCR enhancers (DMSO,
2ME, BSA) increases the yield of MSP and the specificity
of PCR products [50-52]. This is especially important in
the case of GC-rich targets as well as for regions capable of
forming secondary structure, which often result in little or
no amplification. Cycling condition was composed of hot
start at 94°C for 5 min before addition of 1.2 units of Taq
polymerase (Roche), 10 cycles for step I of amplification
was composed of denaturation at 94°C for 50 sec, anneal-
ing at 62°C for 1 min (touch down 0.2°C/cycle), exten-
sion at 72°C for 1 min followed by 27 cycles of step II of
amplification with denaturation for 50 sec at 94°C, 1 min
annealing at 58°C, 1 min extension at 72°C followed by
10 min final extension at 72°C.
Primary amplification condition for the second set of
primers was the same as above except for application of 2
mM MgCl2, and slight reduction in annealing tempera-
ture of steps I and II. Amplification was composed of 10
cycles of 50 sec primary denaturation at 94°C, 1 min
annealing at 58°C (touch down 0.2°C/cycle) and 1 min
extension at 72°C as step I of amplification, followed by
27 cycles of 50 sec denaturation at 94°C, 1 min annealing
at 56°C, 1 min extension at 72°C and 10 min final exten-
sion at 72°C, as step II. Eventually, PCR products were run
in 2% agarose, stained with ethidium bromide and
observed under UV light.
PCR products of primary amplification were used for
MSP. The primers for amplification of methylated
cytosines of promoter 1A were the forward primer; 5' TAT
TGC GGA GTG CGG GTC 3', and the reverse primer; 5'
TCG ACG AAC TCC CGA CGA 3'. The unmethylated CpG
dinucleotide specific primers were the forward primer; 5'
GTG TTT TAT TGT GGA GTG TGG GTT 3', and the reverse
primer; 5' AAC CAA TCA ACA AAC TCC CAA CAA 3'.
MSP was performed in 50 μl PCR reaction mixture con-
taining 1× reaction buffer, 0.2 mM each dNTP, 6 mM
MgCl2, 8 mM β-mercaptoethanol, 0.8 μg/ml BSA, 8%
DMSO, 20 pmol/reaction mixture of methylated or
unmethylated specific primers and 1.2 units of Taq
polymerase. PCR condition was hot start denaturation at
94°C for 5 min, 10 cycles of 50 sec denaturation at 94°C,
40 sec annealing at 56°C (touch down 0.2°C/cycle), 40
sec extension at 72°C followed by 28 cycles of 50 sec
denaturation at 94°C, 40 sec annealing at 54.5°C, 40 sec
extension at 72°C and 10 min final extension at 72°C.
Each set of primers (methylated or unmethylated specific
primers) was used for amplification of tumor and normal
tissue samples as well as negative and positive controls.
PCR products were run in 2% agarose gel, stained with
ethidium bromide and visualized by UV illumination.
Statistical analysis
Fisher's exact test was used to examine the association
between APC promoter hypermethylation and mortality
rate in SCCE patients. Moreover, the Pearson Chi-Square
test was performed to find out possible correlation. Statis-
tical significance was defined as P < 0.05 for Fisher's exact
test and P < 0.001 for Pearson Chi-Square test.
Results
To increase specificity of MSP procedure, four sets of prim-
ers were designed for promoter 1A of APC (NCBI acces-
sion No: U02509) (Figure 1). Two sets of primers were
used in primary amplification leading to either 402 or 320
bp products, which were used in subsequent amplifica-
tion by applying specific primers for either methylated or
unmethylated APC promoter (Figures 1 and 2). The prim-
ers used in the primary amplification were designed
against a part of the promoter sequence without CpG
dinucleotides. This approach eliminated interference of
methylated cytosines and the possible insufficiency of
bisulfite treatment. In addition, enhanced discrimination
of methylated from unmethylated cytosines became pos-
sible in subsequent MSP by applying primers specifically
designed against part of the promoter with a high number
of CpG dinucleotides (Figure 1). MSP products were
either 98 bp for methylated cytosines or 111 bp in case of
unmethylated.
Carrying out MSP on DNA extracted from normal tissues,
111 bp products were obtained, which indicate that nor-
mal tissues are unmethylated (Figure 3). In contrast,
achievement of 98 bp amplification products for 20 out of
45 tumor tissues points out that 44.4% of tumor tissues
are methylated either in one or both alleles of APC.
Among methylated tumor tissues, 13 were heterozygous
for the APC promoter; for which both 111 bp and 98 bp
products were observed (Figure 4). This could happen due
to two reasons; first, heterogeneity of tumor tissues
regarding with their originated cells, such that both cells
containing methylated and cells with unmethylated DNA
are present in the same tissue. The second reason could be
allelic heterozygosity of APC regarding with methylation.
Conversely 7(16%) other tumor tissues were methylated
for both alleles of APC, indicating that their correspond-BMC Cancer 2009, 9:24 http://www.biomedcentral.com/1471-2407/9/24
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ing tissues were homogeneous and composed of only one
type of cells (Figure 3).
To verify consistency of results, three controls were used;
universally methylated DNA, blood DNA of healthy
donors and DNA from the same donors treated with DNA
methylase. As figure 5 shows following bisulfite treatment
of blood DNA of healthy donors and carrying out MSP, it
is negative for APC promoter methylation because it could
only be amplified with unmethylated APC promoter spe-
cific primers. In contrast the same DNA could only be
amplified by methylated APC promoter specific primers if
it was treated with DNA methylase (Figure 5, lane 3). This
provides evidence that bisulfite treatment was complete
and MSP was properly carried out. Further support to our
study was application of universally methylated DNA as
positive control. Here amplification was only possible
with methylated APC promoter specific primers. All the
above controls verified that design of experiments was
proper and the results are valid.
Pathological assessment of tissues showed that tumors
were in different states of differentiation, such that 32
(71%) cases were poorly differentiated, 5 (11%) were
moderately differentiated and 8 (18%) others were well
differentiated. Among poorly differentiated tumors, 13
(41%) were methylated, while 19 (59%) were unmethyl-
ated. This condition was also true for moderately differen-
tiated tissue samples in which 2 out of 5 (40%) tumors
were methylated while 3(60%) others displayed unmeth-
ylated tumors. The highest rate of methylation was found
in well differentiated tumors where 5 out of 8 (62.5%) tis-
sues were methylated (Table 1).
Following up survival of patients for two years revealed a
clear relationship between patients survival and methyla-
tion status of APC  promoter. Fisher's exact test, which
examines the association between APC methylation cir-
cumstances and mortality of patients, showed the statisti-
cally significant correlation (P < 0.05). In addition, the
Pearson Chi-Square test indicted the same relation. This
statistic (X2 = 6.86), at 2 degree of freedom (df), revealed
that there is a significant association (p < 0:001) between
presence of hypermethylated APC promoter and mortality
rate among SCCE patients.
The profile of APC promoter and the amplified products Figure 1
The profile of APC promoter and the amplified products. The products of primary amplification with primers designed 
for promoter sequence without CpG dinucleotides were either 402 or 320 bp. The product of the first step of PCR was used 
for the second step amplification by applying primers, which specifically distinguish methylated from unmethylated cytosines. 
The products of the second amplification were 98 bp for methylated and 111 bp for unmethylated cytosine in CpG islands of 
promoter.BMC Cancer 2009, 9:24 http://www.biomedcentral.com/1471-2407/9/24
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As Table 1 shows, patients with unmethylated tumors, in
all states of differentiation, are more likely to survive for
two or more years after treatment. Moreover, as differenti-
ation status turns from well to poor, survival rate of
patients with methylated promoters increases, while the
converse is true for unmethylated promoters. It should
also be noted that in the case of patients with moderate
and well differentiated tumors additional samples are
required to be included in future studies until a true judg-
ment could be made.
Discussion
Although epidemiological studies have indicated the
highest incidence rate of SCCE occurs in Iran [1-5], never-
theless reports from this part of the world are limited. The
present report is an extension to our former studies [4,10]
on the molecular etiology of SCCE in this region, aiming
PCR products of primary amplification subsequent to bisulfite treatment Figure 2
PCR products of primary amplification subsequent to bisulfite treatment. Lanes 1 and 2 show the 402 bp and lanes 
3 and 4 the 320 bp PCR products. Either of the above PCR products could be used for secondary nested amplification.BMC Cancer 2009, 9:24 http://www.biomedcentral.com/1471-2407/9/24
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to identify potential molecular markers. It is well known
that tumor suppressor genes are mostly affected in SCCE
[9,11,13-17,34,53-57]. As part of a long-term study we
have started analysis of APC  promoter methylation
among tumor suppressor genes such as p15INKb (data not
shown) as well as cell cycle inhibitors such as p14, p15,
p16  and  p21. Epigenetic regulation of gene expression
through promoter methylation is one of the key means of
controlling genes during development and also transcrip-
tional silencing of tumor suppressor genes in cellular
transformation. Promoter methylation pattern varies in
different types of cancers. The highest occurrence of meth-
ylation has been observed in GI cancers involving both
sporadic and inherited types [58].
APC is among tumor suppressor genes whose inactivation
occurs in esophageal cancer as well as other GI cancers
[31]. Inactivation of APC has been shown to be an early
event in tumorigenesis of colorectal and gastric cancer
[59-61], as could be observed with histopathological
examinations and particularly in intestinal tumors in
which sufficient levels of DNA methyltransferase activity
play a role in the early polyp formation in APCMin/+ mice
[62]. Otherwise, APC  hypermethylation has been
observed in less advanced stages of both types of esopha-
geal cancer, similar to p16  and  hMLH1  genes [20,31].
Thus, APC could be considered as an appropriate predic-
tive molecular marker especially for digestive tract can-
cers.
Eads and colleagues have previously shown APC  pro-
moter hypermethylation in Barrett's epithelium, either in
metaplasia, dysplasia and adenocarcinoma of esophagus
[54]. Meltzer's group [32] has demonstrated the signifi-
MSP assessment of tumors versus normal tissues of three patients along with controls Figure 3
MSP assessment of tumors versus normal tissues of three patients along with controls. Lanes 1, 3 and 5 show 
unmethylated APC promoter amplification product of normal nonmalignant tissues with a 111 bp PCR product. Lanes 2, 4 and 
6 are the corresponding methylated tumor tissues of APC promoter as could be observed with 98 bp PCR product. Lane 7; 
negative control (blood) which results in 111 bp product. Lane 10; positive control (universally methylated DNA) with a 98 bp 
product. Lane M; molecular size marker 50 bp (Fermentase).BMC Cancer 2009, 9:24 http://www.biomedcentral.com/1471-2407/9/24
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cance of APC as a molecular marker for both serum and
tissues of patients with adenocarcinoma of esophagus.
Their study showed 92% hypermethylation of APC in ade-
nocarcinoma. The same figure has also been obtained by
Clement et al. [42], who have found APC promoter hyper-
methylation in all instances of Barrett's esophagus and in
95% of adenocacinoma of esophagus. Further study on
the mucosa of patients at risk for developing Barrett's
esophagus, a condition which progresses to adenocarci-
noma of esophagus, has shown 88% methylation of APC
promoter [63]. Moreover, in recent studies APC methyla-
tion has been found to be an appropriate molecular
marker for monitoring tumor recurrence in lung [29]and
bladder [30]cancer in which the presence of hypermethyl-
ated APC in the serum of patients correlates with worse
clinicopathological features of malignancy.
These findings have encouraged us to study the status of
APC promoter methylation in SCCE as well as evaluating
its possible role as a potential molecular marker. Results
indicate that 44.4% of patients with SCCE exhibited
hypermethylation in the APC promoter. These patients
were at a greater risk of death in the two years following
treatment than the unmethylated patients. This finding
indicates that examination of APC  promoter could be
applicable as a potential predictive survival marker for
MSP products of several hemimethylated or cellularly heterogeneous tumor tissues Figure 4
MSP products of several hemimethylated or cellularly heterogeneous tumor tissues. Both 98 bp MSP product of 
the methylated APC promoter and 111 bp MSP product of the unmethylated promoter could be observed in tumor tissues. 
Lanes 1 and 3 represent the MSP products of tumor tissues by applying unmethylated primers. Lanes 2 and 4 show the MSP 
products for the same tissues using methylated primers. Lanes 5 and 6; negative control (blood) which results in 111 bp prod-
uct. Lanes 7 and 8; positive control (universally methylated DNA) with a 98 bp product. M; molecular size marker 50 bp (Fer-
mentase).BMC Cancer 2009, 9:24 http://www.biomedcentral.com/1471-2407/9/24
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almost 50% of SCCE. In addition, combining this marker
with other potential markers such as p53 for which a high
frequency [10,16,33,64-66] of inactivation could be
observed in SCCE would assist better treatment and fol-
low up of disease. Achieving a 44.4% methylation of APC
promoter might well point to the involvement of the same
possible molecular alterations in the etiology of SCCE in
the Iranian population as in other parts of the world. On
MSP results of two positive controls Figure 5
MSP results of two positive controls. Lane 1; MSP product of universally methylated DNA by applying methylated cytosine 
specific primers. Lane 2; the same as lane 1 but unmethylated cytosine specific primers were used. lane 3; MSP product of 
blood DNA extracted from a healthy donor treated with DNA methylase (CpG methyl transferase) and application of methyl-
ated cytosine specific primers, lane 4; the same as lane 3 but unmethylated cytosine specific primers were used.BMC Cancer 2009, 9:24 http://www.biomedcentral.com/1471-2407/9/24
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the other hand, our observation for unmethylated normal
esophagus epithelium is in agreement with Eads et al.
[54], who have shown that normal esophageal epithelium
is unmethylated for promoters such as APC, CDH1, ESR1,
CDKN2A. Thus, it is rational to consider the methylation
status of tumor suppressor genes' promoters as a potential
marker for esophageal cancer.
Comparing our results with Meltzer's group [32] on SCCE
reveals a close similarity (50% versus 44.4%), which
might indicate APC to be among genes whose expression
is affected at the same level in two distinct and geograph-
ically separate populations of the world. In addition, inac-
tivation of APC, which results in β-catenin transcriptional
activation [37,41,42,67], seems to be among prerequisites
for esophageal carcinogenesis. Brabender et al. [28] have
shown that high level of APC ptomoter hypermethylation
is significantly associated with unfavorable clinical out-
comes, lower survival rate and aggressive behavior of
tumors. Our study also shows lower survival rate of
patients with APC hypermethylation. The higher mortal-
ity rate of patients with methylated APC promoter indi-
cates that APC is among determinant genes in esophageal
carcinogenesis. Our former study on p53 tumor suppres-
sor gene [10] further supports this notion as well as other
former studies that have indicated the importance of
tumor suppressor genes in the etiology of SCCE [9-
18,33,34,36].
Our additional study on p15INKb further shows the same
pattern of promoter methylation in SCCE when, for exam-
ple, our finding (16.6%) is compared with other reports
such as Xing et al. [56] who have found 17.6% and Nie et
al. [68] who have shown 19% of P15INKb hypermethyla-
tion. These results further indicate similarity in the process
of tumorigenesis of SCCE.
There are two promoters for transcription of APC; pro-
moter 1A and 1B [69]. In this study we focused on pro-
moter 1A because this promoter is known to play a major
role in carcinogenesis [70]. Previous studies in colon,
breast, lung, endometrial and gastric cancers have indi-
cated that promoter 1B is protected from methylation [70-
72]. It should be noted that transcription might also start
from promoter 1B; however, the product is an inactive
protein. Nevertheless, further study on promoter 1B is rec-
ommended for a better understanding of the role of this
promoter and its possible function in SCCE.
Conclusion
Achieving a comparable pattern of APC promoter hyper-
methylation in the high risk region for SCCE, could be an
indication for common molecular alterations in the etiol-
ogy of SCCE between this region and other parts of the
world. In addition, it raises hope for achieving a common
molecular marker. Nevertheless, further studies are
required to be carried out both on APC and other candi-
date genes, either at epigenetic level or at other molecular
levels such as mutational inactivation and loss of hetero-
zygosity. Identifying correlation between differentiation
status and APC  promoter methylation in conjunction
with lower survival rate of patients with hypermethylated
APC promoter implies the importance of epigenetic con-
trol of tumor suppressor genes in the tumorigenesis of
SCCE, as well as the significant indicatory role of APC
hypermetylation for evaluating tumor malignancy and
predicting survival of SCCE patients subsequent to treat-
ment.
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Table 1: Methylation status and two-year survival of patients following surgery.
Tumor differentiation status * Total Survival rate Methylated tumors Survival rate Unmethylated tumors Survival rate
Poor 32 24 13 (40.6%) 8 (61%) 19 (59%) 16 (84%)
Moderate 5 4 2 (40%) 2 (40%) 3 (60%) 2 (67%)
well 8 4 5 (62%) 1 (20%) 3 (37.5%) 3 (100%)
Total 45 32 20 (44%) 11 (55%) 25 (56%) 21 (84%)
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